Skip to main content
HUALAN GROUP CO.,LTD. logo

HUALAN GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 301027 ISIN · CNE100004MH7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2022-08-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301027

About HUALAN GROUP CO.,LTD.

https://www.gxhl.com

Hualan Group Co., Ltd. specializes in the research, development, and manufacturing of primary pharmaceutical packaging materials. The company's core product portfolio includes high-quality butyl rubber stoppers, aluminum-plastic combination caps, and plastic components designed for injectable medications and infusion sets. These products are engineered to ensure drug stability and compatibility, meeting international quality standards such as GMP. Serving a global clientele of pharmaceutical manufacturers, the group focuses on advanced material science and precision manufacturing to provide secure sealing solutions for vaccines, antibiotics, and blood products. By integrating R&D with large-scale production capabilities, the company maintains a significant role in the pharmaceutical supply chain, emphasizing safety and reliability in drug delivery systems.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the fourth board of directors of 华蓝集团股份公司. It includes details about the meeting date, attendance, and voting results on specific agenda items such as the approval of the 2022 semi-annual report and a special report on the use of raised funds. The document references the actual 2022 semi-annual report and related disclosures being published elsewhere (on the cninfo website and newspapers), indicating this document itself is not the report but an announcement of board decisions related to it. The document length is short (1158 characters), and it serves as a formal disclosure of board meeting resolutions rather than containing the full financial report or detailed financial data. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2022-08-28 Chinese
关于第四届董事会第五次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific matters discussed at the fifth meeting of the fourth board of directors. It includes opinions on the use of raised funds, related party fund occupation, and external guarantees for the 2022 half-year period. The document is short (1015 characters) and focuses on compliance and independent director opinions rather than presenting full financial statements or detailed financial analysis. It does not contain comprehensive financial data or constitute a full interim report. It is also not an announcement of voting results or a management report. The nature of the document aligns with an Audit Report / Information (AR) as it provides independent audit opinions on specific financial and compliance matters for a half-year period, but is not a full annual or interim report. Therefore, the best classification is AR with high confidence. H1 2022
2022-08-28 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) for 华蓝集团股份公司, indicating it is a summary of the company's interim financial report. It contains key financial data and performance metrics for the half-year period, such as revenue, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary derived from the full half-year report and advises investors to read the full report for comprehensive details. The length is under 5,000 characters but contains substantive financial data and analysis, not merely an announcement or a link to a report. Therefore, it qualifies as an Interim / Quarterly Report (IR). H1 2022
2022-08-28 Chinese
关于部分董事、监事减持股份预披露的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding planned share reductions by certain directors and supervisors of the company. It details the number of shares held, the planned reduction quantities, the reasons for reduction, and compliance with relevant regulations. There is no financial data, earnings information, or report publication mentioned. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is 2503 characters, which is consistent with a typical insider trading announcement rather than a full report or regulatory filing. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-08-05 Chinese
关于更换保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's sponsor representative for its IPO and ongoing supervision. It includes details about the replacement of the sponsor representative and a brief biography of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes at the board level. This fits the category of a regulatory announcement about a procedural change related to the IPO process, which is best classified under Regulatory Filings (RNS). The document length is short and it is an announcement, not a report or detailed financial disclosure.
2022-07-14 Chinese
公司首次公开发行部分限售股解禁上市流通提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on certain shares previously subject to lock-up following the company's initial public offering (IPO). It includes specifics about the number of shares becoming freely tradable, shareholder commitments, dates, and regulatory compliance confirmations. The document is not a financial report, earnings release, or management discussion, but rather a formal notice about share circulation changes post-IPO. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance with stock exchange rules, not a report or financial statement itself.
2022-07-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.